mk-0873
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2004 (NCT00132730)
Timeline
Indications
Mechanism of action
Phosphodiesterase 4 and 5 (PDE4 and PDE5) inhibitor
- Phosphodiesterase 4INHIBITOR
Phosphodiesterase 4 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(NC1CC1)c1cn(-c2cccc(C#Cc3ccc[n+]([O-])c3)c2)c2ncccc2c1=O- Mol. weight
- 422.44 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL485629 ↗
Also known as
- mk0873
- mk 0873
- mk-0873
- mk-0873
- mk-0873
- mk-0873
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01235728 | Phase 1 | Nov 1, 2010 | Merck |
| NCT01140061 | Phase 1 | May 1, 2010 | Merck |
| NCT00132769 | Phase 2 | Jan 1, 2005 | Merck |
| NCT00132730 | Phase 2 | Jun 1, 2004 | Merck |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 4 | 4 | 2 | 2004 |
1 organizations
Page 1 / 1